Clinical trial · Interventional
Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy
Impact de la Composition Corporelle Sur la dosimétrie de la radiothérapie Interne vectorisée au 177Lu-PSMA
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Castration Resistant Prostatic Neoplasms | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 177Lu-PSMA-617 + SPECT/CT dosimetry | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- COCORIVO
- description
- Patients with mCRPC treated with 177Lu-PSMA-617 undergoing additional SPECT/CT acquisitions and body composition analysis
- interventionNames
- Radiation: 177Lu-PSMA-617 + SPECT/CT dosimetry
Primary outcomes (1)
- measure
- Tumor and organ-at-risk dosimetry as a function of body composition
- timeFrame
- After cycle 1 of 177Lu-PSMA treatment (approximately week 1)
- description
- Dosimetry (Gy) of all tumors and organs at risk (salivary glands, bone marrow, kidneys) evaluated by SPECT/CT at 72-96H post-injection. Patients classified into two categories based on median body composition of the study population.
Secondary outcomes (2)
- measure
- Comparison of SUV vs SUL in 68Ga-PSMA PET/CT and 177Lu-PSMA SPECT/CT
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Signed informed consent * Male, age \>= 18 years * Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment * PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT * Affiliated to or beneficiary of a social security scheme Exclusion Criteria: * Patient unable to understand the study or comply with study constraints (language barrier, psychological, geographic...) * Patient under legal protection (tutelle, curatelle, sauvegarde de justice)
References
Publications (0)
Data not yet available